Albumin-bound paclitaxel: a next-generation taxane

By W. Gradishar. Expert Opinion on Pharmacotherapy, 2006

658 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/4bac6bdd45824a28e9ac3f53f0ffd83e3087cbb6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. D. Kingston
2. Samuel A. Wickline
3. Vaughn Barry
4. N. Desai
5. Kyle Steenland
6. A. Winquist

In Oncology

1. D. Kingston
2. Vaughn Barry
3. Zhesheng Chen
4. N. Desai
5. Kyle Steenland
6. A. Winquist

Citations in the corpus

• Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy (2007, background): “A recent example of the impact of nanomedicine in drug delivery is underscored by the success of AbraxaneTM, an albumin nanoparticle conjugate of paclitaxel, and the first FDA-approved anti-cancer agent in this emerging class of drug formulations [39].”
• Perfluorooctanoic Acid (PFOA) Exposures and Incident Cancers among Adults Living Near a Chemical Plant (2013, methodology): “Paclitaxel, a drug which induces cytotoxicity by derangement of the cell’s c ytoskeleton, has been conjugated to human albumin to produce the drug Abraxane, approved for use in m etastatic breast cancer in 2005 [31].”
• Challenges in Development of Nanoparticle-Based Therapeutics (2012, methodology): “The size distribution of nab-paclitaxel nanoparticles in solution was narrow with a mean particle size of 130 nm as determined by dynamic laser light scattering (58).”
• Tubulin-Interactive Natural Products as Anticancer Agents (2008, background): “A recent review concludes “nab technology has increased the therapeutic index of paclitaxel compared with the conventional, solvent-based formulation (32).”
• Nanotechnological applications in medicine. (2007, background): “Abraxane, a nanoparticle version of paclitaxel bound to albumin, achieves water solubility without harsh excipients, has been shown to be more effective than previous formulations of paclitaxel, and is the first such chemotherapeutic nanoparticle approved by the FDA [44 ].”
• Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. (2016, background): “Abraxane1 has many advantages over paclitaxel, including longer blood circulation time and lower hypersensitivity (Gradishar, 2006).”